2023³â ´ç´¢º´½ÅÁõ ½ÉÆ÷Áö¾ö : 2023-01-28±³À°ÀÏÀÚ : 2023-01-28
±³À°Àå¼Ò : ¹é¹ü±â³ä°ü ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
2023³â ´ç´¢º´½ÅÁõ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : À¯ÁöÀÎ
¿¬¶ôó : 02-714-9072
À̸ÞÀÏ :
diabetes@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 4 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í »çÀüµî·Ï: 1¸¸¿ø, ÇöÀåµî·Ï:2¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 01-28 ¹é¹ü±è±¸±â³ä°ü 13:00~13:05 Àλ縻 ±è³Èñ(°í·ÁÀÇ´ë ¾È»êº´¿ø)
±³À°½Ã°£ 01-28 ¹é¹ü±è±¸±â³ä°ü 13:05~13:15 History of Research Group of Diabetic Kidney Disease in KDA ÃÖµ¿¼·(°í·ÁÀÇ´ë)
±³À°½Ã°£ 01-28 ¹é¹ü±è±¸±â³ä°ü 13:15~13:35 Paradigm shift in clinical practice, eGFR and/or albuminuria as indicator for DKD? ±è¼ÒÇå(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 01-28 ¹é¹ü±è±¸±â³ä°ü 13:35~13:55 New ADA_ASN joint statement ¼¹ÌÇý(¼øõÇâ´ë ±¸¹Ìº´¿ø)
±³À°½Ã°£ 01-28 ¹é¹ü±è±¸±â³ä°ü 13:55~14:15 Choice of Renal endpoints in DKD trials ±Ç¼øÈ¿(¼øõÇâ´ëÇб³)
Åä·Ð 01-28 ¹é¹ü±è±¸±â³ä°ü 14:15~14:35 ÆгÎÅäÀÇ ±èµ¿¸²(°Ç±¹´ëÇб³)
±³À°½Ã°£ 01-28 ¹é¹ü±è±¸±â³ä°ü 14:35~14:55 The effect of Finerenone on diabetic kidney disease ±è°æ¾Æ(µ¿±¹´ë Àϻ꺴¿ø)
±³À°½Ã°£ 01-28 ¹é¹ü±è±¸±â³ä°ü 14:55~15:15 The effect of GLP-1 RA on diabetic kidney disease ÀüÀçÇÑ(Ä¥°î°æºÏ´ëÇб³ º´¿ø)
±³À°½Ã°£ 01-28 ¹é¹ü±è±¸±â³ä°ü 15:15~15:35 Possible emerging drugs for diabetic kidney disease ¹®ÁÖ¿µ(°æÈñ´ëÇб³º´¿ø)
Åä·Ð 01-28 ¹é¹ü±è±¸±â³ä°ü 15:35~15:55 ÆгÎÅäÀÇ ÃÖ¿ø¼®(Àü³²È¼øº´¿ø)
ÈÞ½Ä 01-28 ¹é¹ü±è±¸±â³ä°ü 15:55~16:20 Coffee Break ()
±³À°½Ã°£ 01-28 ¹é¹ü±è±¸±â³ä°ü 16:20~16:40 Cardiologist view ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 01-28 ¹é¹ü±è±¸±â³ä°ü 16:40~17:00 Nephrologist view À¯ÅÂÇö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 01-28 ¹é¹ü±è±¸±â³ä°ü 17:00~17:20 Endocrinologist view ±è³²ÈÆ(°í·Á´ëÇб³ ¾È¾Ïº´¿ø)
Åä·Ð 01-28 ¹é¹ü±è±¸±â³ä°ü 17:20~17:40 ÆгÎÅäÀÇ ±è¼ö°æ(±¹¸³°æ»ó´ëÇб³º´¿ø)